Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2013 11:00 ET | Source: ACT Foundation of Canada

7,000 Students in Durham Region High Schools to Be Equipped With Lifesaving Skills Each Year!

DURHAM REGION, ONTARIO--(Marketwired - Sept. 25, 2013) - Today, the Advanced Coronary Treatment (ACT) Foundation and its supporting partners announce the official launch of the ACT High...
September 09, 2013 05:00 ET | Source: Aquilo Capital Management

Aquilo Capital Management Submits Open Letter to the Board of Directors and Fellow Shareholders of Astex Pharmaceuticals

SAN FRANCISCO, CA--(Marketwired - Sep 9, 2013) - Dear members of the Board and fellow shareholders of Astex Pharmaceuticals, We are the Managing General Partner and Portfolio...
August 20, 2013 06:00 ET | Source: Alchemia

Alchemia Reports Record Fondaparinux Quarterly Profit Share

BRISBANE, AUSTRALIA--(Marketwired - Aug 20, 2013) - A$3.9m profit share for quarter ending 30 June 2013 Total Alchemia fondaparinux profit share of A$9.6m...
August 20, 2013 01:15 ET | Source: Immune Pharmaceuticals Inc

EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Aug. 20, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) (the "Company") and Immune Pharmaceuticals Ltd....
August 07, 2013 17:00 ET | Source: Immune Pharmaceuticals Inc

EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.

Almost 92% of Votes Cast in Favor of Proposals Merger Expected to close in August 2013 TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq and Nasdaq...
August 01, 2013 00:10 ET | Source: Immune Pharmaceuticals Inc

EpiCept Reports Second Quarter 2013 Operating and Financial Results

Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals TARRYTOWN, N.Y., Aug. 1, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq OMX Stockholm...
June 20, 2013 00:56 ET | Source: Immune Pharmaceuticals Inc

EpiCept Issues Notice of Special Meeting of Stockholders on August 6 to Approve Important Aspects of the Proposed Merger with Immune Pharmaceuticals

Positive Vote Required to Enable Merger Closing Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX: EPCT) today issued notice that stockholders of EpiCept are invited to the Special...
June 19, 2013 02:18 ET | Source: AstraZeneca PLC

ASTRAZENECA AND BRISTOL-MYERS SQUIBB ANNOUNCE TOP-LINE RESULTS FOR SAVOR-TIMI-53 CARDIOVASCULAR OUTCOMES TRIAL OF ONGLYZA® (SAXAGLIPTIN)

19 June, 2013 AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes...
June 03, 2013 00:01 ET | Source: Immune Pharmaceuticals Inc

EpiCept Announces New Crolibulin Data Presented at ASCO 2013 Support Further Evaluation in Anaplastic Thyroid Cancer

TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that new data supporting further...
May 20, 2013 00:33 ET | Source: Immune Pharmaceuticals Inc

EpiCept Reports First Quarter 2013 Operating and Financial Results

PRELIMINARY PROXY STATEMENT FOR MERGER FILED WITH SEC TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX:...